Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality.
MASLD
arterial stiffness
death
steatotic liver disease
vascular age
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
13 May 2024
13 May 2024
Historique:
revised:
10
04
2024
received:
20
02
2024
accepted:
30
04
2024
medline:
14
5
2024
pubmed:
14
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
Several reports show a significant association between metabolic dysfunction-associated steatotic liver disease (MASLD) and arterial stiffness (estimated pulse wave velocity [ePWV]) as a surrogate marker of vascular age. We investigate whether ePWV as arterial stiffness in MASLD is associated with all-cause/cause-specific mortality. This cohort study was based on the third National Health and Nutrition Examination Survey (NHANES, 1988-1994) and NHANES 2007-2014 and linked mortality datasets through 2019. Cox regression models assessed the association between ePWV categorized by quartile and all-cause/cause-specific mortality among individuals with MASLD. During the follow-up of a median of 26.3 years (interquartile range: 19.9-27.9), higher levels of ePWV among individuals with MASLD were associated with increased all-cause mortality, which remained significant after adjusting for demographic, lifestyle, clinical, and metabolic risk factors. Furthermore, higher ePWV in MASLD was associated with higher cardiovascular mortality. There was a 44% (hazard ratio: 1.44, 95% confidence interval: 1.32-1.58) increase in all-cause mortality and a 53% (hazard ratio: 1.53, 95% confidence interval: 1.32-1.77) increase in cardiovascular mortality for every 1 m/s increase in ePWV in MASLD. However, there was no significant association between ePWV and cancer-related mortality. Sensitivity analyses using the NHANES 2007-2014 dataset showed results identical to the original analysis. Higher ePWV in MASLD was associated with a higher risk of all-cause and cardiovascular mortality beyond traditional cardiovascular risk factors. Screening for ePWV in individuals with MASLD may be an effective and beneficial approach to reducing all-cause and cardiovascular mortality.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Several reports show a significant association between metabolic dysfunction-associated steatotic liver disease (MASLD) and arterial stiffness (estimated pulse wave velocity [ePWV]) as a surrogate marker of vascular age. We investigate whether ePWV as arterial stiffness in MASLD is associated with all-cause/cause-specific mortality.
METHODS
METHODS
This cohort study was based on the third National Health and Nutrition Examination Survey (NHANES, 1988-1994) and NHANES 2007-2014 and linked mortality datasets through 2019. Cox regression models assessed the association between ePWV categorized by quartile and all-cause/cause-specific mortality among individuals with MASLD.
RESULTS
RESULTS
During the follow-up of a median of 26.3 years (interquartile range: 19.9-27.9), higher levels of ePWV among individuals with MASLD were associated with increased all-cause mortality, which remained significant after adjusting for demographic, lifestyle, clinical, and metabolic risk factors. Furthermore, higher ePWV in MASLD was associated with higher cardiovascular mortality. There was a 44% (hazard ratio: 1.44, 95% confidence interval: 1.32-1.58) increase in all-cause mortality and a 53% (hazard ratio: 1.53, 95% confidence interval: 1.32-1.77) increase in cardiovascular mortality for every 1 m/s increase in ePWV in MASLD. However, there was no significant association between ePWV and cancer-related mortality. Sensitivity analyses using the NHANES 2007-2014 dataset showed results identical to the original analysis.
CONCLUSION
CONCLUSIONS
Higher ePWV in MASLD was associated with a higher risk of all-cause and cardiovascular mortality beyond traditional cardiovascular risk factors. Screening for ePWV in individuals with MASLD may be an effective and beneficial approach to reducing all-cause and cardiovascular mortality.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Murag S, Ahmed A, Kim D. Recent epidemiology of nonalcoholic fatty liver disease. Gut Liver. 2021; 15: 206–216.
Li AA, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 2020; 14: 168–178.
Mattace‐Raso FU, van der Cammen TJ, Hofman A et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113: 657–663.
Jaruvongvanich V, Chenbhanich J, Sanguankeo A, Rattanawong P, Wijarnpreecha K, Upala S. Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta‐analysis. Eur. J. Gastroenterol. Hepatol. 2017; 29: e28–e35.
Chung GE, Choi SY, Kim D et al. Nonalcoholic fatty liver disease as a risk factor of arterial stiffness measured by the cardioankle vascular index. Medicine (Baltimore). 2015; 94: e654.
Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357–1365.
Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction‐associated fatty liver disease is associated with increased all‐cause mortality in the United States. J. Hepatol. 2021; 75: 1284–1291.
Konyn P, Ahmed A, Kim D. Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2023; 29: S43–S57.
Kim D, Ahmed A. Nonalcoholic fatty liver disease in early life and all‐cause and cause‐specific mortality. Hepatobiliary Surg Nutr. 2022; 11: 317–319.
Lee JH, Kim D, Kim HJ et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 2010; 42: 503–508.
Reference Values for Arterial Stiffness C. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur. Heart J. 2010; 31: 2338–2350.
Greve SV, Blicher MK, Kruger R et al. Estimated carotid‐femoral pulse wave velocity has similar predictive value as measured carotid‐femoral pulse wave velocity. J. Hypertens. 2016; 34: 1279–1289.
Vlachopoulos C, Terentes‐Printzios D, Laurent S et al. Association of estimated pulse wave velocity with survival: a secondary analysis of SPRINT. JAMA Netw. Open 2019; 2: e1912831.
Kim D, Vazquez‐Montesino LM, Li AA, Cholankeril G, Ahmed A. Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease. Hepatology 2020; 72: 1556–1568.
Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 2023; 79: 1542–1556.
van Sloten TT, Schram MT, van den Hurk K et al. Local stiffness of the carotid and femoral artery is associated with incident cardiovascular events and all‐cause mortality: the Hoorn study. J. Am. Coll. Cardiol. 2014; 63: 1739–1747.
Heffernan KS, Stoner L, London AS, Augustine JA, Lefferts WK. Estimated pulse wave velocity as a measure of vascular aging. PLoS ONE 2023; 18: e0280896.
Jae SY, Heffernan KS, Park JB et al. Association between estimated pulse wave velocity and the risk of cardiovascular outcomes in men. Eur. J. Prev. Cardiol. 2021; 28: e25–e27.
Heffernan KS, Wilmoth JM, London AS. Estimated pulse wave velocity and all‐cause mortality: findings from the Health and Retirement Study. Innov. Aging 2022; 6: igac056.
Greve SV, Laurent S, Olsen MH. Estimated pulse wave velocity calculated from age and mean arterial blood pressure. Pulse (Basel). 2017; 4: 175–179.
Adeva‐Andany MM, Adeva‐Contreras L, Fernandez‐Fernandez C, Gonzalez‐Lucan M, Funcasta‐Calderon R. Elastic tissue disruption is a major pathogenic factor to human vascular disease. Mol. Biol. Rep. 2021; 48: 4865–4878.
Meffert PJ, Baumeister SE, Lerch MM, Mayerle J, Kratzer W, Volzke H. Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. Am. J. Gastroenterol. 2014; 109: 1404–1414.
Hajifathalian K, Torabi Sagvand B, McCullough AJ. Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study. Hepatology 2019; 70: 511–521.